Mode
Text Size
Log in / Sign up

Patient Buddy App reduced avoidable readmissions in cirrhosis inpatients compared to standard of care.

Patient Buddy App reduced avoidable readmissions in cirrhosis inpatients compared to standard of car…
Photo by Logan Voss / Unsplash
Key Takeaway
Consider the Patient Buddy App for reducing avoidable readmissions in cirrhosis inpatients.

This randomized clinical trial evaluated the Patient Buddy App (HIT) versus standard of care (SOC) in 464 subjects comprising 232 dyads of cirrhosis inpatients and adult caregivers. The study was conducted across multiple centers including Virginia Commonwealth University, Mayo, and the Department of Veterans Affairs. Follow-up occurred for 30 days post-discharge. Due to COVID-19, an unplanned study redesign required a combined HIT versus SOC comparison. Most dyads reported satisfaction with the app regarding tolerability. Safety data regarding adverse events, serious adverse events, and discontinuations were not reported.

The primary outcome measured avoidable readmissions. Results showed significantly higher rates in the SOC group versus the HIT group with an odds ratio of 2.14 (95% CI 1.01-4.54) and a p-value of 0.04. Absolute numbers indicated 19.8% of patients in the SOC group versus 10.3% in the HIT group experienced avoidable readmissions. When analyzing data after removing pre-COVID HIT+ visits patients, avoidable readmissions remained significantly higher in SOC versus HIT with an odds ratio of 2.41 (95% CI 1.02-5.69) and a p-value of 0.040. Absolute numbers for this subgroup were 19.8% versus 9.3%.

Secondary outcomes assessed all-cause readmissions. Rates were higher in SOC versus HIT with absolute numbers of 48% versus 30% and a p-value of 0.005. The study limitations include the combined comparison group necessitated by the pandemic. Practice relevance is constrained by the specific inpatient cirrhosis population and the unplanned nature of the intervention rollout.

Study Details

Study typeRct
EvidenceLevel 2
PublishedMay 2026
View Original Abstract ↓
BACKGROUND AND AIMS: Reducing avoidable readmissions in cirrhosis is challenging. Enhanced engagement using health information technology (HIT) interventions and caregivers lowered readmissions in an open-label study of the Patient Buddy App (PBA). Aim: Multicenter trial of PBA versus standard of care (SOC) to reduce avoidable readmissions. APPROACH AND RESULTS: An open-label, randomized clinical trial was performed at 3 sites to study the effect of PBA (HIT) versus SOC in cirrhosis inpatients with adult caregivers (dyads). Initial randomization was 1:1:1 between SOC, HIT only, and HIT+ visits. However, due to COVID-19, an unplanned study redesign required a combined HIT versus SOC. Primary outcome: Avoidable readmissions (decided by a blinded monitoring board). Secondary outcomes were all-cause readmission and stakeholder input. PBA focused on medication adherence, cognitive testing, and symptoms, and was remotely monitored by study staff. In all, 464 subjects (232 dyads) were enrolled [Virginia Commonwealth University (VCU): 120, Mayo: 40, Department of Veterans Affairs (VA): 72; 116 dyads/group]. Avoidable readmissions were significantly higher in SOC versus HIT (19.8% vs. 10.3%, p =0.04) with OR of 2.14 (95% CI 1.01-4.54) and remained significant even after removing pre-COVID HIT+ visits patients (19.8% vs. 9.3%, p =0.040) with OR of 2.41 (95% CI 1.02-5.69). All-cause readmissions were higher in SOC versus HIT (48% vs. 30%, p =0.005). App evaluation/engagement: 1660 alerts were sent; mostly related to HE. Most dyads were satisfied with the app. CONCLUSIONS: In a multicenter randomized clinical trial of 464 cirrhosis inpatients and their CGs across several practice settings, the PBA was associated with lower avoidable readmissions at 30 days post-discharge compared to SOC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.